Investor Relations

The Dermapharm Group develops pharmaceuticals and other healthcare products in its core therapeutic areas at four corporate locations, where experienced experts conduct development and authorisation activities – including designing and funding clinical trials. Once authorisation is granted, newly developed products are generally put into production in-house. In total, the Group manufactures about 90% of the pharmaceutical product portfolio itself.

The focal points of the development work are:

• Expanding the portfolio of off-patent branded pharmaceuticals in dermatology
• Further developing allergy therapy product range
• Developing science-based food supplements
• Developing new phytoextracts
• Further developing the range of medical devices

The Dermapharm Group has been operating in Austria, Switzerland, Croatia, Poland and Ukraine for many years now. In order to further expand its business with branded pharmaceuticals and other healthcare products, the Group has formed subsidiaries in Italy and Spain. Country-specific portfolios are formed/developed based in each case on a detailed analysis of market conditions, with compounds developed and manufactured by the Group in particular receiving marketing authorisation. This enables the Group to gradually enlarge its portfolio and the respective sales and distribution structures as it expands into new markets. For instance, the Dermapharm Group is expanding into other countries in Europe, Asia and the Americas with its CE-certified and internationally patented medical devices bite away^® and Herpotherm^®.

Another key aspect of the Group's internationalisation efforts is the acquisition of companies with international operations. With the acquisition of Euromed, Dermapharm is represented with herbal extracts in Spain. Allergopharma and Cernelle also contribute to further internationalisation. Most recently, the Dermapharm Group gained market access to Western and Southern Europe with the acquisition of Arkopharma. 

Acquiring individual products, portfolios and companies has always been part of Dermapharm's business strategy and a key success factor for its continued growth. Since its formation in 1991, the Group has steadily expanded its product offering through successful acquisitions in Germany and abroad. This includes, for instance, the acquisition of attractive patented medical devices and pharmaceutical manufacturers, which complement the Group's portfolio ideally and expand its offering in growth markets. Another aim when making these types of acquisitions is to further increase the potential of the newly acquired companies by optimising processes and incorporating the companies in the Group's production and logistics structures. The Dermapharm Group continually reviews specific growth opportunities and pursues promising acquisition options that fit its strategic alignment.